Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial Academic Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Coronary Disease
  • Immunoglobulin Fab Fragments
  • Myocardial Ischemia
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex

abstract

  • Acute reductions in ischemic events after percutaneous coronary intervention by abciximab are sustained over follow-up to at least 1 year. Early periprocedural myocardial infarctions suppressed by this therapy are associated with long-term mortality rates.

publication date

  • April 20, 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10208997

Additional Document Info

start page

  • 1951

end page

  • 8

volume

  • 99

number

  • 15